{"id":"W2795488377","doi":"10.1016/s1470-2045(18)30146-3","title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Daiichi-Sankyo; ArQule","keywords":"Medicine; Placebo; Sorafenib; Internal medicine; Hepatocellular carcinoma; Clinical endpoint; Population; Gastroenterology; Cirrhosis; Adverse effect; Intention-to-treat analysis; Phases of clinical research; Clinical trial; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001867938,0.001446811,0.003598375,0.0003454596,0.0003437811,0.001253177,0.0007678154,0.001547778,0.004440847],"category_scores_gemma":[0.00162175,0.0006579878,0.003251202,0.0003980381,0.0008241161,0.001077855,0.0003046638,0.002768948,0.0008904613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008949303,"about_ca_system_score_gemma":0.0009265543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001136376,"about_ca_topic_score_gemma":0.003359194,"domain_scores_codex":[0.9993711,0.0003373035,0.00004640712,0.00008375929,0.00004529701,0.0001161191],"domain_scores_gemma":[0.9992735,0.0002337025,0.0001470879,0.00007000945,0.00006135244,0.0002142939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9678597,0.001215862,0.0005356604,0.00143255,0.002765107,0.00005954309,0.00005182931,0.000274413,0.003954833,0.00008716482,0.0007819323,0.02098131],"study_design_scores_gemma":[0.9602156,0.03451303,0.002243071,0.00007093959,0.001342022,0.00006089256,0.00002682613,0.0001962328,0.0004512283,0.0001112631,0.0007490267,0.00001977284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9639395,0.02620675,0.001326522,0.00104402,0.001002391,0.002554157,0.001769563,0.00021589,0.00194126],"genre_scores_gemma":[0.981756,0.00934457,0.001735427,0.001186094,0.000458766,0.001435244,0.001658703,0.00005028886,0.002374924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004440847,"threshold_uncertainty_score":0.0148561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07760832321810575,"score_gpt":0.3859511444927207,"score_spread":0.308342821274615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}